linsitinib   Click here for help

GtoPdb Ligand ID: 7423

Synonyms: ASP-7487 | OSI 906 | OSI-906 | OSI906
Compound class: Synthetic organic
Comment: Linsitinib (OSI-906) is an orally bioavailable small-molecule inhibitor of IGF-1R and insulin receptor [1]. Note that the chemical structure in the PubChem record is for the non-stereo molecule. The INN record specifies stereochemistry as shown in our chemical structure.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 89.33
Molecular weight 421.19
XLogP 4.93
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Nc1nccn2c1c(nc2C1CC(C1)(C)O)c1ccc2c(c1)nc(cc2)c1ccccc1
Isomeric SMILES Nc1nccn2c1c(nc2[C@@H]1C[C@](C1)(C)O)c1ccc2c(c1)nc(cc2)c1ccccc1
InChI InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+
InChI Key PKCDDUHJAFVJJB-VLZXCDOPSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Linsitinib is a drug candidate for the treatment of various types of cancer, and thyroid eye disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Linsitinib is a dual IGF-1R/insulin receptor (IR) kinase inhibitor. This inhibits IGF-1R-driven tumorigenesis and metastasis [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00924989 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Phase 3 Interventional Astellas Pharma Inc
NCT07753603 Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) Phase 3 Interventional Sling Therapeutics, Inc.
NCT06112340 Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3 Interventional Sling Therapeutics, Inc.
NCT05276063 A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3 Interventional Sling Therapeutics, Inc.